What sector does Remus Pharmaceuticals L belong to?

Remus Pharmaceuticals L operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of REMUS?

As of the latest available quote, REMUS traded at ₹1,911.30. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of REMUS?

Remus Pharmaceuticals L has a price-to-earnings (P/E) ratio of about 48.81. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of REMUS?

The market capitalisation of Remus Pharmaceuticals L is approximately ₹1,037 Cr.

Is Remus Pharmaceuticals L profitable?

For its latest reported financial year, Remus Pharmaceuticals L recorded a net profit margin of about 5.39%.

Does REMUS pay a dividend?

Remus Pharmaceuticals L currently has a dividend yield of about 0.05%.

What is the return on equity (ROE) of REMUS?

Remus Pharmaceuticals L has a return on equity (ROE) of about 12.20%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of REMUS?

Over the past 52 weeks, REMUS has traded between a low of ₹580.00 and a high of ₹987.50.

Remus Pharmaceuticals L

REMUS NSE Healthcare Pharmaceuticals

₹1,911.30

-2.60%

Delayed · cached 15 min

Fair value analysis

REMUS

Remus Pharmaceuticals L

₹893.05

Close used for this calculation

₹899.45Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

57/100

Profitability19/25

Returns7/25

Balance Sheet21/25

Efficiency10/25

Growth14/25

Good

Quality radar

Consensus fair value

₹899.45

Near FV

▲ +0.7% against the close used

Model range ₹68.37 – ₹1,413.67

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹68.37Fair value₹899.45Bull₹1,413.67

FairClose

52-week traded range

52W low ₹582.8552W high ₹961.65

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Remus Pharmaceuticals L closed at ₹893.05, 0.7% below the consensus fair value of ₹899.45 drawn from 9 valuation models.

Financial DNA score 57/100 — Good. P/E of 28.0x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹68.37

-92.3%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹462.40

-48.2%

√(22.5 × EPS × BVPS)

EPS=31.39, BVPS=302.73 · outside Graham range (P/E 28, P/B 3) — asset-light, treat as a rough floor

Graham Formula

₹1,413.67

+58.3%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=20%, FD=7%

P/E Fair Value

₹1,120.62

+25.5%

EPS × 35.7x (sector P/E)

EPS=31.39, Sector P/E=35.7x

Peter Lynch (PEG)

₹784.75

-12.1%

EPS × Growth% (PEG = 1 is fair)

EPS=31.39, g=25%

EV/EBITDA

₹906.83

+1.5%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=600M

Book Value (P/B)

₹469.23

-47.5%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=302.73, ROE=12.2%, g=6%, r=10%

Reverse DCF

₹893.05

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 11.9% | Historical: 25%

Margin of Safety

₹574.70

-35.6%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=766.27, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer